MDX-060. Medarex.
Medarex is developing the antibody MDX-060 for the potential treatment of CD30+ lymphomas, such as Hodgkin's disease and anaplastic large cell lymphomas. Phase I/II clinical trials were underway by December 2002.
Hu
Xiu Feng
XF
The Austin Research Institute, Austin Health, Heidelberg 3084, Victoria, Australia.
Xing
Pei Xiang
PX
D000818:Animals; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004354:Drug Screening Assays, Antitumor; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D017730:Ki-1 Antigen / Q000276:immunology*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000276:immunology
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D017730:Ki-1 Antigen; C510955:iratumumab